Pharmaceutical

What Pharmaceutical does

Pharmpur GmbH is an owner-managed German specialty CDMO (contract development and manufacturing organization) headquartered in Königsbrunn, Germany, focused on the production of liquid, sterile medicinal products and medical devices filled into syringes, carpules, and vials. Founded in 1992, the company has evolved from a specialist laboratory into a full-range provider (Komplettanbieter) offering integrated Fill & Finish services spanning synthesis, high-purification, compounding, filling, labelling, sterilization, secondary packaging, and analytics under a single regulatory and quality umbrella. Its core product categories comprise perfluorocarbon liquids (PFCL), medical-grade silicone oils, viscous media (hydrogels, hyaluronic acid derivatives), and water-based preparations; the company has developed proprietary process IP including the H-Value quality criterion for PFCL impurity control and specialized silicone oil purification methods to remove toxic oligosiloxanes. Manufacturing is governed by EU GMP, ISO 13485, CE marking, and EU MDR (effective May 2020), with active oversight by the Government of Upper Bavaria and Notified Body DQS Medizinprodukte GmbH.

Pharmpur operates a B2B sales-led contract manufacturing model, serving pharmaceutical and medical device customers across four primary verticals: ophthalmology (core, including ocular endotamponades and viscoelastics for surgical use), orthopedics (gel-like substances with low endotoxin requirements), aesthetics (sterile viscous injectables), and urology (sterile liquid formulations). Pricing is quote-based and project-specific, reflecting customized purification procedures, validation, and regulatory support rather than standardized unit pricing. The company's competitive position rests on a modular platform architecture that combines nest filling, air-bubble-free filling of highly-viscous media, and terminal sterilization of temperature-sensitive products, enabling parallel manufacturing of multiple niche products with consistent quality via a Bracketing validation approach.

The firm is led by Managing Director Dr. Dirk-Henning Menz alongside a fully PhD-credentialed executive bench covering COO, CBDO, Manufacturing, Regulatory Affairs, QA, QC, Technology, and Finance. The 2020 Königsbrunn site expansion — comprising new offices, a second clean room facility, a 66 kWp photovoltaic system, and an enterprise ERP implementation — substantially expanded both physical capacity and operational sophistication. The customer base is not publicly disclosed and no revenue, funding round, or ownership-investor data is available; Pharmpur has no parent company, no subsidiaries, and no known institutional investment, consistent with its founder/family-controlled status. Geographic footprint is concentrated in the DACH region with no explicit claims of global coverage, although EU GMP/PIC/S compliance and CE marking position it for broader EU service delivery.

Name

Pharmaceutical

Legal name

Pharmpur GmbH

Website

https://pharmpur.de

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

Pharmpur GmbH is a German specialty CDMO that contract-manufactures liquid, sterile medicinal products and medical devices filled in syringes and vials, with proprietary purification know-how in perfluorocarbon liquids and silicone oils for ophthalmology, orthopedics, aesthetics, and urology customers.

Ownership category

akta.pro rank

Headquarters

HQ city

Königsbrunn

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Others

Revenue model

1. Contract Manufacturing Services (Fill & Finish): Full-service contract manufacturing for liquid sterile medicinal products and medical devices. Production encompasses all steps including synthesis and purification, compounding, filling, labeling, sterilization, and packaging. Offered as complete Fill & Finish processes under one roof.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Pharmpur GmbH is an owner-managed family company providing full-service contract manufacturing (Komplettanbieter) of liquid, sterile medicinal products and medical devices filled in syringes, carpules, and vials. The company offers integrated Fill & Finish services under one roof encompassing synthesis, purification, compounding, filling, labeling, sterilization, and packaging. Core product categories include perfluorocarbon liquids, medical-grade silicone oils, viscous media (hydrogels, hyaluronic acid), and water-based sterile preparations, primarily serving ophthalmology, orthopedics, aesthetics, and urology applications.

Product overview

Pharmpur GmbH is an owner-managed family company offering contract manufacturing of liquid, sterile medicinal products and medical devices. The portfolio centers on Fill & Finish services for products filled in syringes, carpules, and vials, supported by integrated Synthesis & Purification and Analytics business units. Core products include Perfluorocarbon Liquids, Silicone Oils, Viscous Media (hydrogels, hyaluronic acid derivatives), and Water-based Preparations. The company employs a modular manufacturing platform enabling flexible, efficient production of niche products with platform technologies including nest filling, air bubble-free filling of highly-viscous media, and terminal sterilization.

Differentiator

Problem solved

Functional benefit

Products and services

• Perfluorocarbon Liquids (PFCL) Organic compounds with all H-atoms replaced by F-atoms, chemically inert with low surface tension and high gas solubility, used for medical applications including ocular endotamponade and other ophthalmic procedures. Manufactured under Pharmpur's proprietary H-Value Quality Criterion and specialized purification processes.
• Silicone Oils Medical-grade silicone oils purified using Pharmpur's proprietary method to remove oligosiloxanes, residual OH-groups, and ionic compounds. Used as ocular endotamponades and for other medical applications requiring ultra-pure silicone oils.
• Viscous Media Gel-like substances including hydrogels, hyaluronic acid, cross-linked hyaluronic acid, modified HPMC, and Newtonian/non-Newtonian fluids with very low endotoxin content, for ophthalmological and other medical applications requiring specific rheological properties.
• Water-based Preparations Sterile water-based mixtures of active substances and adjuvants in buffering systems, processed through terminal sterilization in clean rooms using dedicated equipment, for ophthalmic and other sterile applications.
• Fill & Finish Contract Manufacturing Services Full-service contract manufacturing for liquid medicinal products and medical devices filled in syringes, carpules, and vials. Includes compounding, secondary packaging, sterilization, and final packaging — offered as a complete one-roof service for pharmaceutical and medical device companies.
• Research & Development Services Synthesis of new materials, bonding of substances to substrate materials, and production of supplementary materials for medical use, primarily hydrogels, including tailor-made purification processes for customer-specific applications.
• Synthesis & Purification Services Synthesis and purification of raw materials for Fill & Finish processes, implemented in own laboratories on kilo scale, with purification procedures individually tailored to impurity profiles of each perfluorocarbon liquid and silicone oil.
• Analytics Services Quality control, stability testing, product care, and R&D analytics including chromatographic methods (HPLC, GC/MS), physical-chemical processes (FT-IR, UV/VIS, rheometry), and pharmacopoeial processes (Ph. Eur., USP).
• Modular Concepts Manufacturing Platform Uniform platform of individual modules enabling flexible response to contract manufacturing requirements with modular processes for positioning, filling, labelling, and packing. Incorporates the Bracketing approach for validation efficiency and supports parallel manufacturing of numerous niche products with uniform high quality.

Quantifiable outcome

• Over 15 tonnes of CO2 saved through photovoltaic system in first two months
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered minor.

• AiF (Arbeitsgemeinschaft industrieller Forschungsvereinigungen)minorStrategic or Co-development PartnerFunding organization for industrial research. Pharmpur has received funding for projects including 'Development of perfluoroalkylalkanes' and 'Decubitus prophylaxis via transdermal oxygen supply'. AiF served as project management.
• LifePhotonics GmbHminorStrategic or Co-development PartnerCooperation partner in Magic Eye project for laser cataract surgery technology. Other partners include BYTEC Medizintechnik GmbH, Fiberware Generalunternehmen für Nachrichtentechnik GmbH, University Eye Hospital Tübingen, and Institut für Lasertechnologien in der Medizin und Messtechnik Universität Ulm (ILM).
• BYTEC Medizintechnik GmbHminorStrategic or Co-development PartnerCooperation partner in Magic Eye project for laser cataract surgery technology.
• Fiberware Generalunternehmen für Nachrichtentechnik GmbHminorStrategic or Co-development PartnerCooperation partner in Magic Eye project for laser cataract surgery technology.
• University Eye Hospital TübingenminorStrategic or Co-development PartnerAcademic partner in Magic Eye project for laser cataract surgery technology.
• Institut für Lasertechnologien in der Medizin und Messtechnik Universität Ulm (ILM)minorStrategic or Co-development PartnerAcademic partner in Magic Eye project for laser cataract surgery technology.
• EU Project FUNFLUOSminorStrategic or Co-development PartnerEU-funded research project on functional fluorides. Pharmpur participated in this European research collaboration.
• JWGU Frankfurt (Johann Wolfgang Goethe University)minorStrategic or Co-development PartnerCooperation partner in Safe Light project for LED ocular illumination technology.
• HS Ulm (Hochschule Ulm)minorStrategic or Co-development PartnerCooperation partner in Safe Light project for LED ocular illumination technology.
• EPIGAP Optronic GmbHminorStrategic or Co-development PartnerCooperation partner in Safe Light project for LED ocular illumination technology.
• VDI (Verein Deutscher Ingenieure)minorStrategic or Co-development PartnerProject management for Magic Eye project (laser for cataract surgery).
• University Clinics Giessen and MarburgminorStrategic or Co-development PartnerPartnered with Pharmpur for humanitarian aid to Ukraine. Organized transport of donated endotamponades and viscoelastics to western Ukraine ophthalmological centers. Connected Pharmpur with Ukrainian Vitreological Society.
• Ukrainian Vitreological SocietyminorStrategic or Co-development PartnerPartner connected via University Clinics Giessen and Marburg. Received humanitarian aid from Pharmpur for ophthalmological centers in western Ukraine.

Scale indicators3 records

Recent moves9 records

Expansion highlights5 records

Others

• Bausch + Lomb: Major global ophthalmology products company producing pharmaceuticals, devices, and consumer health products for eye care. Comparable to Pharmpur only insofar as the ophthalmology segment overlap (ocular endotamponades, surgical ophthalmic preparations), though Bausch + Lomb is a downstream product customer/competitor rather than a contract manufacturer.
• Alcon: Swiss-headquartered global ophthalmology medical device and pharmaceutical company. Comparable to Pharmpur only in the sense of shared ophthalmology therapeutic focus (surgical ophthalmic preparations, viscoelastics), but operates as a downstream product company rather than a contract manufacturer.

Broad incumbents

• Recipharm: Swedish CDMO operating multiple sterile injectable manufacturing sites across Europe. Comparable to Pharmpur as a broader incumbent European sterile Fill & Finish CDMO that competes for the same customer wallet share, though at materially larger scale.
• Catalent: US-headquartered global CDMO with strong aseptic fill-finish and sterile injectable capabilities. Comparable to Pharmpur at the category level as a sterile injectable CDMO, though operating at significantly greater scale and geographic reach.
• Fareva: French CDMO with multiple sites producing sterile liquid, semi-solid, and other pharmaceutical dosage forms. Comparable to Pharmpur as a European contract manufacturer offering sterile liquid manufacturing and packaging services.

Direct peers

• Siegfried Holding: Swiss-listed CDMO with sterile fill-finish capabilities for injectables and other dosage forms. Comparable to Pharmpur as a European contract manufacturer focused on sterile liquid manufacturing for pharmaceutical customers across multiple therapeutic areas.
• CARBOGEN AMCIS: Swiss CDMO with capabilities in API development, sterile injectable manufacturing, and drug product services. Comparable to Pharmpur as a European specialty contract manufacturer offering sterile liquid drug product development and manufacturing.
• Vetter Pharma: German CDMO specializing in aseptic fill & finish of injectable drugs in syringes, vials, and cartridges. Comparable to Pharmpur because both are German-based, GMP-certified contract manufacturers offering sterile liquid Fill & Finish for pharmaceutical customers across multiple therapeutic areas.
• Aenova Group: German pharmaceutical CDMO offering development, manufacturing, and packaging of solid, semi-solid, and sterile liquid dosage forms. Comparable to Pharmpur as a German contract manufacturer with sterile liquid capabilities serving pharmaceutical customers.
• Rommelag (Holopack): German CMO/CDMO specializing in Blow-Fill-Seal aseptic filling technology for sterile liquid products. Comparable to Pharmpur as a German-headquartered contract manufacturer focused on aseptic liquid packaging for pharma and medical device customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmpur

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaceutical